Clinical Trials
36 trialsAutologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
Beijing Boren Hospital
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
ALPS
Fondazione IRCCS Policlinico San Matteo di Pavia
ReAL
Fondazione IRCCS Policlinico San Matteo di Pavia
EUREKA
Fondazione IRCCS Policlinico San Matteo di Pavia
ProDigALIty
Fondazione IRCCS Policlinico San Matteo di Pavia
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Mayo Clinic
ITA-WebNet
Fondazione IRCCS Policlinico San Matteo di Pavia
B-SCR-MM
Ohio State University Comprehensive Cancer Center
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Peking University People's Hospital
Rapid dFLC Response Predict CHR in AL Amyloidosis
Peking University People's Hospital
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Brigham and Women's Hospital
GlycAL
Fondazione IRCCS Policlinico San Matteo di Pavia
BE.Amycon Biobank & Data Registry UZ Leuven
Universitaire Ziekenhuizen KU Leuven
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Boston Medical Center
Teclistamab-Daratumumab in AL Amyloidosis
Columbia University
MICA
Brigham and Women's Hospital
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
UNC Lineberger Comprehensive Cancer Center
EAR
University Hospital, Essen
Screening for AL Amyloidosis in Smoldering Multiple Myeloma
Tufts Medical Center
Teclistamab in Newly Diagnosed Mayo Stage IIIB AL Amyloidosis
Peking Union Medical College Hospital
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Columbia University
Registry of Older Patients With Cancer
UNC Lineberger Comprehensive Cancer Center
Teclistamab in Previously Treated AL Amyloidosis
Peking Union Medical College Hospital
Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis
Beijing Boren Hospital
Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis
Hadassah Medical Organization
Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
Peking University People's Hospital
ICAR
Leiden University Medical Center
NIMMS
St. Olavs Hospital
Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis
Peking University People's Hospital
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
Peking University People's Hospital
Daratumumab/Daratumumab and Hyaluronidase-fihj in Combination With Pomalidomide and Dexamethasone for the Treatment of Patients With Newly Diagnosed AL Amyloidosis: a Prospective, Multicenter, Single-arm Study
First Affiliated Hospital of Wenzhou Medical University
Daratumumab for Patients With Light Chain Amyloidosis
Nanjing University School of Medicine
FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
Nanjing University School of Medicine
RaDaR
UK Kidney Association